Rebulla P, Giovanetti A M, Petrini G, Mezzetti M, Sirchia G
Surgery. 1985 Apr;97(4):463-6.
We report the results of a pilot study on predeposit autotransfusion for elective surgery. In 2 years 319 U, each consisting of 350 ml of blood, were donated by 206 patients. Each patient gave 1, 2, or 3 U according to hematocrit levels within 10 days of undergoing surgery on the gastrointestinal tract, lung, liver, kidney, brain, thyroid, arteries, or breast. A hemoglobin drop of about 0.8 gm/dl occurred after each blood donation. A total of 259 autologous and 128 homologous U were transfused to 166 patients during surgery or within postoperative day 4; 40 patients required no blood transfusion. About 70% of patients did not need homologous blood products in addition to autologous units. The most active team of surgeons and anesthesiologists covered about 40% of the patients' blood needs during the study period with autologous units. No patient experienced untoward reactions before, during, or after surgery. Surgeons' and anesthesiologists' responses to the program improved during the study as soon as the advantages of the procedure became clearer. However, gentle pressure from the Transfusion Center was essential for the program's expansion. The patients' acceptance was excellent. We conclude that predeposit autotransfusion is a safe and feasible procedure for transfusion treatment in elective surgery.
我们报告了一项关于择期手术预存式自体输血的初步研究结果。在两年内，206名患者捐献了319单位血液，每单位为350毫升。每位患者根据血细胞比容水平，在接受胃肠道、肺、肝、肾、脑、甲状腺、动脉或乳房手术前10天内捐献1、2或3单位血液。每次献血后血红蛋白下降约0.8克/分升。在手术期间或术后第4天内，共向166名患者输注了259单位自体血和128单位异体血；40名患者无需输血。约70%的患者除自体血外不需要异体血制品。在研究期间，最积极的外科医生和麻醉医生团队用自体血满足了约40%患者的用血需求。没有患者在手术前、手术期间或手术后出现不良反应。随着该程序的优势变得更加明显，在研究期间外科医生和麻醉医生对该程序的反应有所改善。然而，输血中心的适度推动对于该程序的推广至关重要。患者的接受度很高。我们得出结论，预存式自体输血是择期手术输血治疗的一种安全可行的方法。
